Jacqueline Mock

Jacqueline Mock

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
HTHanne L. P. Tytgat
Hanne L. P. Tytgat
CLChia-Wei Lin
Chia-Wei Lin
MLMikail D. Levasseur
Mikail D. Levasseur
MTMarkus B Tomek
Markus B Tomek
CRChristoph Rutschmann
Christoph Rutschmann
TKTimothy G. Keys
Timothy G. Keys
Glycosylation of proteins profoundly impacts their physical and biological properties. Yet our ability to engineer novel glycoprotein structures remains limited. Established bacterial glycoengineering platforms require secretion of the acceptor protein to the periplasmic space and preassembly of the oligosaccharide substrate as a lipid-linked precursor, limiting access to protein and glycan substrates respectively. Here, we circumvent these bottlenecks by developing a facile glycoengineering platform that operates in the bacterial cytoplasm. The Glycoli platform leverages a recently discovered site-specific polypeptide glycosyltransferase together with variable glycosyltransferase modules to synthesize defined glycans, of bacterial or mammalian origin, directly onto recombinant proteins in the E. coli cytoplasm. We exploit the cytoplasmic localization of this glycoengineering platform to generate a variety of multivalent glycostructures, including self-assembling nanomaterials bearing hundreds of copies of the glycan epitope. This work establishes cytoplasmic glycoengineering as a powerful platform for producing glycoprotein structures with diverse future biomedical applications.

25 November 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JMJacqueline Mock
Jacqueline Mock
MSMarco Stringhini
Marco Stringhini
Alessandra VillaAlessandra Villa
Alessandra Villa
MWMichael Weller
Michael Weller
TWTobias Weiss
Tobias Weiss
DNDario Neri
Dario Neri
Significance: Antibody-cytokine fusion proteins have been successfully applied for the treatment of preclinical models of cancer and have yielded promising results in early clinical trials. The antibody moiety redirects the immunostimulatory payload to the tumor to boost the antitumor immune response. However, especially at early time points after administration, the relatively high concentration of the antibody-cytokine conjugate in blood can lead to severe side effects due to peripheral activation of cytokine receptors. Therefore, protein engineering approaches are needed to develop antibody-cytokine conjugates that selectively regain their immunostimulatory activity on antigen binding in the tumor. In this work, we have developed an antibody-cytokine conjugate that meets these criteria and shows antitumor activity in preclinical models of cancer.

24 February 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JMJacqueline Mock
Jacqueline Mock
CPChristian Pellegrino
Christian Pellegrino
DNDario Neri
Dario Neri
Engineered cytokine products represent a growing class of therapeutic proteins which need to be tested for biological activity at various stages of pharmaceutical development. In most cases, dedicated biological assays are established for different products, in a process that can be time-consuming and cumbersome. Here we describe the development and implementation of a universal cell-based reporter system for various classes of immunomodulatory proteins. The novel system capitalizes on the fact that the signaling of various types of pro-inflammatory agents (e.g., cytokines, chemokines, Toll-like receptor agonists) may involve transcriptional activation by NF-κB. Using viral transduction, we generated stably-transformed cell lines of B or T lymphocyte origin and compared the new reporter cell lines with conventional bioassays. The experimental findings with various interleukins and with members of the TNF superfamily revealed that the newly-developed “universal” bioassay method yielded bioactivity data which were comparable to the ones obtained with dedicated conventional methods. The engineered cell lines with reporters for NF-κB were tested with several antibody-cytokine fusions and may be generally useful for the characterization of novel immunomodulatory products. The newly developed methodology also revealed a mechanism for cytokine potentiation, based on the antibody-mediated clustering of TNF superfamily members on tumor-associated extracellular matrix components.

Verified
Journal Article
Open access
PDF file
SDSheila Dakhel
Sheila Dakhel
CLChristian Lizak
Christian Lizak
MMMattia Matasci
Mattia Matasci
JMJacqueline Mock
Jacqueline Mock
VAVilla Micaela Alessandra
Villa Micaela Alessandra
SCSamuele Cazzamalli
Samuele Cazzamalli
Antibody-cytokine fusion proteins (immunocytokines) are gaining importance for cancer therapy, but those products are often limited by systemic toxicity related to the activity of the cytokine payload in circulation and in secondary lymphoid organs. Tumor necrosis factor (TNF) is used as a pro-inflammatory payload to trigger haemorrhagic necrosis and boost anti-cancer immunity at the tumor site. Here we describe a depotentiated version of TNF (carrying the single point mutation I97A), which displayed reduced binding affinity to its cognate receptor tumor necrosis factor receptor 1 (TNFR-1) and lower biocidal activity. The fusion of the TNF(I97A) mutant to the L19 antibody promoted restoration of anti-tumor activity upon accumulation on the cognate antigen, the alternatively spliced EDB domain of fibronectin. In vivo administration of high doses (375 μg/Kg) of the fusion protein showed a potent anti-tumor effect without apparent toxicity compared with the wild type protein. L19-TNFI97A holds promise for the targeted delivery of TNF activity to neoplastic lesions, helping spare normal tissues.

8 June 2023 in mAbs
Verified
Journal Article
Open access
AEAbdullah Elsayed
Abdullah Elsayed
CPChristian Pellegrino
Christian Pellegrino
LPLouis Plüss
Louis Plüss
FPFrederik Peissert
Frederik Peissert
RBRamon Benz
Ramon Benz
DNDario Neri
Dario Neri
Antibody-based therapeutics represent an important class of biopharmaceuticals in cancer immunotherapy. CD3 bispecific T-cell engagers activate cytotoxic T-cells and have shown remarkable clinical outcomes against several hematological malignancies. The absence of a costimulatory signal through CD28 typically leads to insufficient T-cell activation and early exhaustion. The combination of CD3 and CD28 targeting products offers an attractive strategy to boost T-cell activity. However, the development of CD28-targeting therapies ceased after TeGenero’s Phase 1 trial in 2006 evaluating a superagonistic anti-CD28 antibody (TGN1412) resulted in severe life-threatening side effects. Here, we describe the generation of a novel fully human anti-CD28 antibody termed “E1P2” using phage display technology. E1P2 bound to human and mouse CD28 as shown by flow cytometry on primary human and mouse T-cells. Epitope mapping revealed a conformational binding epitope for E1P2 close to the apex of CD28, similar to its natural ligand and unlike the lateral epitope of TGN1412. E1P2, in contrast to TGN1412, showed no signs of in vitro superagonistic properties on human peripheral blood mononuclear cells (PBMCs) using different healthy donors. Importantly, an in vivo safety study in humanized NSG mice using E1P2, in direct comparison and contrast to TGN1412, did not cause cytokine release syndrome. In an in vitro activity assay using human PBMCs, the combination of E1P2 with CD3 bispecific antibodies enhanced tumor cell killing and T-cell proliferation. Collectively, these data demonstrate the therapeutic potential of E1P2 to improve the activity of T-cell receptor/CD3 activating constructs in targeted immunotherapeutic approaches against cancer or infectious diseases.

22 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CNCesare Di Nitto
Cesare Di Nitto
EGEttore Gilardoni
Ettore Gilardoni
JMJacqueline Mock
Jacqueline Mock
LNLisa Nadal
Lisa Nadal
TWTobias Weiss
Tobias Weiss
RLRoberto De Luca
Roberto De Luca
Interferon-gamma (IFNγ) is one of the central cytokines produced by the innate and adaptive immune systems. IFNγ directly favors tumor growth control by enhancing the immunogenicity of tumor cells, induces IP-10 secretion facilitating (CXCR3+) immune cell infiltration, and can prime macrophages to an M1-like phenotype inducing proinflammatory cytokine release. We had previously reported that the targeted delivery of IFNγ to neoplastic lesions may be limited by the trapping of IFNγ-based products by cognate receptors found in different organs. Here we describe a novel fusion protein consisting of the L19 antibody, specific to the alternatively spliced extra-domain B of fibronectin (EDB), fused to a variant of IFNγ with reduced affinity to its cognate receptor. The product (named L19-IFNγ KRG) selectively localized to tumors in mice, showed favorable pharmacokinetic profiles in monkeys and regained biological activity upon antigen binding. The fusion protein was investigated in two murine models of cancer, both as monotherapy and in combination with therapeutic modalities which are frequently used for cancer therapy. L19-IFNγ KRG induced tumor growth retardation and increased the intratumoral concentration of T cells and NK cells in combination with anti-PD-1.